3 April 2019

World Parkinson’s Day (April 11th) aims to raise awareness of Parkinson’s disease (PD) and the desperate need for effective new treatments. A recent review authored by members of the BioMed21 Collaboration identifies advances that could be implemented to better understand pathological processes, improve disease outcome, and reduce dependence on animal models.  Many people may not be aware of how animals suffer in labs, used for research into Parkinson’s disease, when the answers we need may lie with patient-centred research and not animal testing.

For people, muscle tremors, or loss of fine control of movement, may be the first outward sign of Parkinson’s disease, but these motor symptoms are not the start. The death of dopamine-producing neurons in the brain ultimately cause the tremors, but the damage starts long before the tremors are apparent. Modelling this gradual loss of neurons is not possible in animals. Simulation of Parkinson’s disease in animals often uses injections of toxins directly into the brain. This destroys the dopamine-producing neurons, but the effects are instant and short-lived, compared to the slow progressive decline that occurs over decades in people. [Read more…]

18 January 2019

Organ-on-Chip in Development (ORCHID) is a European Horizon 2020 project that aims to capitalise on the innovative technology that is organ-on-chip, or OoC. The ORCHID consortium is made up of seven partners from six European countries and was launched in 2017 with the overall aim of building a network of OoC stakeholders, including academic, research, industrial and regulatory institutions, in order to move OoCs from laboratories to a more global awareness and utility.

We are in the midst of a ‘drugs drought‘, which means there could be no more new, approved compounds by around 2070 unless we radically alter the current drug discovery paradigm. Using animals as models of human disease for predicting safety and efficacy of novel drugs has proven to be time consuming, costly and about as effective as tossing a coin—with failure rates running as high as 99.6 % for some conditions.  While the reasons underpinning the failure of new chemical entities to reach the clinic, and successfully remain there, are complex and multi-factorial, there is no doubt that one of the greatest limitations for identifying new therapeutics for human diseases is the deficiencies in the animals employed/manipulated as models of the human condition.  [Read more…]

14 January 2019

In November 2018, India joined other innovative economies working to replace the use of animals in laboratory experiments with the launch of the Indian Society for Alternatives to Animal Experiments (ISAAE) during the country’s second national conference on alternatives in New Delhi. Humane Society International, founder of the BioMed21 Collaboration, was a lead sponsor and keynote speaker at the conference, which created a platform for national and international scientists from various backgrounds to engage in discussions pertaining to the present and future of alternatives to the use of animals in research and testing.

The chief guest of the event, Dr Renu Swarup, Secretary of the Department of Biotechnology, graced the inaugural ceremony with an encouraging speech for the audience, comprised of scientists and students alike. The informative keynote lecture by HSI Vice President of Research & Toxicology, Troy Seidle, kickstarted the event, focusing on the need for human biology-based pathways to study human diseases and test new products, and exploring the vision of expediting 21st century science through the BioMed21 Collaboration. [Read more…]

13 December 2018

Diabetes treatment is often touted as the poster-child success of animal research; after all, insulin was first discovered in dog pancreas almost 100 years ago. A lot has changed since then. Or at least it should have. The reality is that billions of research dollars are still wasted on ineffective animal models of diabetes that are not translating to therapies delivering effective glycaemic control for patients. For instance, oral insulin and nicotinamide were both therapeutic interventions that showed promise in animals but failed in humans. A new review – ‘Future Roadmaps for Precision Medicine Applied to Diabetes: Rising to the Challenge of Heterogeneity’ – from clinical experts and published in the Journal of Diabetes Research, reveals the gap between animal models of diabetes and the human condition and calls for alternative, non-animal approaches to drive advances in research that are ‘clinically translatable’ and that apply existing and evolving methods of relevance to human focused research.

The crude experimentation with dogs in the 1920s provided us with a basic understanding of diabetes and it is clear that animals can only ever provide an incomplete understanding of disease. Research questions now are too complex to be answered by a model that superficially resembles the human condition; only human-focused models can answer the in-depth sophisticated questions that our improved understanding of disease have allowed us to formulate, and the explosion in biotechnology and the ‘omics revolution that have occurred in recent years are providing the human relevant tools to enable this. Shifting focus towards human studies has helped to reveal that diabetes is a multifactorial, heterogeneous spectrum of metabolic disorders with environmental and genetic elements, but it seems that a continued reliance on animal models has failed to provide a detailed understanding of disease pathogenesis or provide the elusive cures.  [Read more…]

23 October 2018

Thrombosis-on-a-chip, vasculature-on-a-chip and engineered models of human cardiac fibrosis are just a few of the new technologies revolutionizing research into human cardiovascular disease—a condition responsible for 17 million deaths per annum globally. A new study entitled Cardiovascular Disease Models: A Game Changing Paradigm in Drug Discovery and Screening, published this week in the journal Biomaterials by bioengineering scientists from the University of Toronto, proposes a new paradigm for research into cardiovascular diseases. The new paradigm is rooted in a human-specific understanding of disease mechanisms, coupled with application of novel microphysiological and computational tools based on human biology to create more predictive laboratory models of the human disease.

Lead author, Dr. Houman Savoji, CIHR & FRQNT postdoctoral fellow in Prof. Milica Radisic’s Laboratory, explained that, “In vitro and in silico disease models are frequently used to complement or confirm data acquired from animal models. However it is apparent that the application of these two fast-growing and emerging platforms, given their reduced costs, more ethical and more accurate, human-relevant outcomes, are becoming promising substitutes for animal models. The development of multi-functional platforms that combine mechanistic knowledge about the pathophysiology and etiology of cardiovascular diseases with ever-expanding engineering technologies (i.e., micro/nanofabrication) and advances in stem cell biology, brings hope to the mandate of improving translation in drug discovery and concomitantly reducing the use of experimental animals in preclinical research.” [Read more…]

21 September 2018

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and a major public health concern, particularly for the very young and very old. Around the world, sepsis kills more people than AIDS, breast cancer and prostate cancer combined. The mortality rate can be as high as 50%, and those who survive are often left with long-term consequences that may include physical and psychological disabilities.

Sepsis becomes fatal as a consequence of multiple organ failure caused by an overwhelming cascade of inflammatory mediators released into the bloodstream. But exactly how this response to infection is regulated, and whether it is in fact a regulated response, remains uncertain. Some authors have suggested that the body goes through different immune states while fighting sepsis, starting by activation of immunity and then reaching immune paralysis or exhaustion. Current treatments have shown limited efficacy and patient outcome is in most cases unpredictable.  [Read more…]

9 August 2018

A new study by scientists from the Vrije Universiteit Brussel calls for a new gold standard in research to treat non-alcoholic steatohepatitis (NASH), an obesity-linked chronic liver disease impacting millions of people of all ages worldwide. The disease can progress to liver cancer if untreated, creating a massive strain on an already overburdened healthcare system. The study, published in Pharmacological Research, proposes a human-specific roadmap to better understand the biological mechanisms behind NASH, a crucial missing link in the effort to develop effective, and urgently-needed, treatments for the disease.

Dr Robim Rodrigues and Prof Tamara Vanhaecke of the Vrije Universiteit Brussel, lead authors on the study, commented that “In vitro models that reflect population diversity and specific mechanisms of the disease are already valuable tools today.” Modern techniques, including transcriptomics, proteomics, and metabolomics, are rapidly becoming more reliable and may therefore provide insights into the mechanistic background of NASH.” Dr Rodrigues explains that several drugs in development for NASH have been tested using in vitro models, clearly indicating the value of these systems in NASH R&D. He is optimistic that further development of predictive, human-based tools will provide a more cost-effective and reliable methodology for much-needed drug development for NASH liver disease.  [Read more…]

31 July 2018

Recommendations to come out of a workshop attended by representatives of the U.S. National Institutes of Health, the Federal Drug Administration, big pharma, and academia hold a dire warning: unless we invest more funding in human- rather than animal-based medical research to better predict which new drugs will treat human disease, the development of new drugs could dry up completely in the next 50 years. The paper, Recommendations toward a human pathway-based approach to disease research, published in the journal Drug Discovery Today summarizes the results of a two-day workshop that took place at the National Institutes of Health in June 2017.

The BioMed21 workshop, co-organized by the National Institutes of Health, The Humane Society of the United States, and Humane Society International, presented a comprehensive overview of existing efforts to prioritize human-based biology for health research and proposed key recommendations to revitalize the drug discovery process.  [Read more…]

10 July 2018

The world’s most industrialized economies have been increasingly investing in technologies and opportunities that will eventually replace animal-models used in toxicology and biomedical research. In South America, too, a number of scientists have already recognized this trend and are interested in doing research that do not rely on animal models. Now, the BioMed21 Collaboration, a group of scientists and other stakeholders who together work towards replacing the use of animals in research, has published a paper in the journal Drug Discovery Today entitled Human-specific approaches to brain research for the 21st century: A South American perspective. The paper reports on a two-day workshop that took place in Rio de Janeiro, in May 2017, organized by Humane Society International in collaboration with D’Or Institute for Research and Education (IDOR).

The meeting brought together leading scientists, representing scientific institutions in Brazil and in Argentina, Brazil’s National Council for Scientific and Technological Development (CNPq), and other stakeholders to leverage existing national and international projects to improve health research and to engage scientists to shape a new human-specific paradigm for biomedical research in the region. [Read more…]

3 July 2018

Humane Society International, co-founder of the BioMed21 Collaboration, teamed up with global fashion brand H&M and together they financially supported China’s 8th Workshop on Alternative Methods, held June 11-13 in Shanghai. The event provided more than 200 scientists from industry, government bodies and academia with in-depth theoretical and hands-on experience in contemporary “new approach methods” (NAM) applicable to regulatory and research environments.

A keynote lecture by The Humane Society of the United State’s Chief Scientific Officer, Dr Andrew Rowan, kicked off the meeting on the theme of ‘Move to a new research paradigm.’ Dr Rowan was later interviewed for shangzhibo tv, where he expressed optimism regarding China’s potential role in further developing and promoting new approach methods, concluding that China’s proven ability to embrace new technologies could allow them to become a ‘world beater’ in alternative methods. [Read more…]

19 June 2018

Earlier this year, the US Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) published its new Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products. This seminal document offers a consensus perspective, incorporating the views of 16 federal regulatory and research agencies, several interagency workgroups and public opinion.

The Roadmap provides a conceptual framework supporting the development, evaluation and use of the “new approach methodologies” (NAM), expediting the use of human relevant methods and reducing reliance on existing animal-based approaches to risk assessment. Its overall aim is: “To expedite the use of 21st-century science to protect and improve public health, federal agencies and stakeholders will work together to build a new framework to enable development, establish confidence in, and ensure use of new approaches to toxicity testing that improve human health relevance and reduce or eliminate the need for testing in animals.” [Read more…]